Live Roundtable: What Is the Biggest Bottleneck Holding Back Cell and Gene Therapy? - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Live Roundtable: What Is the Biggest Bottleneck Holding Back Cell and Gene Therapy?

  • October 23, 2026

  • 1 min

Share

Objective:

Present expert perspectives on the main barriers to making cell and gene therapies widely accessible and where the industry should focus its efforts.

Approach:
  • Format: A roundtable produced by IBTV in collaboration with The Medicine Maker and moderated by Dalip Sethi of Terumo Blood and Cell Technologies.
  • Participants: The discussion features Louis Cicchini of Cencora, Michael Baker of Fujifilm Biotechnologies, and Heather Purvis of Title21 Health Solutions.
  • Topics: Participants consider industry priorities, opportunities for collaboration, and whether AI and other emerging technologies could help address barriers to patient access.
Key Findings:
  • The article identifies complex manufacturing, fragmented data systems, regulatory requirements, limited care sites, and uncertain reimbursement as potential barriers.
  • The context does not report a specific bottleneck selected by the participants or detailed roundtable conclusions.
Interpretation:

The article introduces a discussion of challenges to broader access; the provided context does not specify which challenge the experts consider the greatest.

Limitations:
  • The supplied context is an introduction to the roundtable and does not include its discussion or conclusions.
Sources:

Original Source(s)

Related Content